Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-008: MK-1026 versus chemoimmunotherapy in previously untreated CLL/SLL without TP53 aberrations
CTR20230821Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of suvorexant in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Aug 2023; status: active.
02
Drugs
suvorexant
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20230821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230821.